Glenmark Pharmaceuticals S.a.

Dnyaneshwar E Shelke

Neelima Khairatkar-Joshi

Abraham Thomas

Laxmikant Atmaram Gharat

Daisy Manish Shah

Malini Bajpai

Sanjib Das

Shailesh Ramesh Pardeshi

Rajendra L Harde

The present disclosure is directed to novel carbocyclic compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, R, R, R, n, m and p are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (ROR&#x3b3;t). These compounds prevent, inhibit, or suppress the action of ROR&#x3b3;t and are therefore useful in the treatment of ROR&#x3b3;t mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer.

Carbocyclic compounds as ROR gamma modulators

The present disclosure is directed to novel carbocyclic compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, R, R, R, n, m and p are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (ROR&#x3b3;t). These compounds prevent, inhibit, or suppress the action of ROR&#x3b3;t and are therefore useful in the treatment of ROR&#x3b3;t mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer. 

Growing community of inventors

Maharashtra, India

Dnyaneshwar E Shelke